Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly

P. Crainich, N. S. Jenny, Z. Tang, A. M. Arnold, L. H. Kuller, T. Manolio, A. R. Sharrettu, R. P. Tracy

Research output: Contribution to journalArticlepeer-review

Abstract

Elevated circulating plasminogen activator inhibitor-1 (PAI-1) may increase risk of cardiovascular disease (CVD). The 4Galleleofthe4G/5G PAI-1 promoter polymorphism is associated with higher levels of PAI-1. We examined the association of PAI-1 4G/5G genotype and CVD events in the elderly participants of the Cardiovascular Health Study (CHS). We measured 4G/5G genotype in a nested case-control study within the CHS. Cases included incident angina, myocardial infarction (MI), and stroke. 4G/5G genotype was not found to be associated with markers of fibrinolysis or CVD risk in the selected elderly cohort. There were no differences in genotype frequencies by case-control status (5G/5G frequency 16-22%; χ 2 P = 0.07). The 5G allele was not associated with incident CVD events when individuals with at least one 5G allele were compared to 4G/4G homozygotes. The presence of at least one 4G allele was likewise not associated with incident CVD when those with 4G/4G and 4G/5G genotypes were compared to 5G/5G homozygotes. Our results suggest that the PAI-1 4G/5G promoter polymorphism is not associated CVD risk factors or incident CVD events in the elderly.

Original languageEnglish (US)
Pages (from-to)1799-1804
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume1
Issue number8
DOIs
StatePublished - Aug 2003

Keywords

  • Cardiovascular disease
  • Elderly
  • Fibrinolysis
  • Genetic polymorphism
  • Plasminogen activator inhibitor-1

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly'. Together they form a unique fingerprint.

Cite this